How the EU Pharmaceutical Reform is redefining decision-making across the pharmaceutical industry
Executive Insight
The European pharmaceutical industry is entering a new era.
The EU Pharmaceutical Package, the most significant overhaul of European pharmaceutical legislation in over two decades, is often described as a regulatory reform. While technically correct, this definition underestimates its true significance.
This is not simply a new set of rules.
It represents a fundamental shift in how Europe expects pharmaceutical innovation to create value. Innovation will no longer be measured solely by scientific excellence or successful regulatory approval. Increasingly, it will also be assessed through its contribution to patient access, healthcare sustainability and security of supply.
For pharmaceutical companies, this changes the rules of strategic decision-making.
Regulatory choices will influence investment priorities, clinical development, evidence generation, market access strategies, manufacturing resilience and, ultimately, commercial success.
In this environment, Regulatory Affairs can no longer operate as a downstream compliance function. It must become a strategic capability embedded in business decision-making.
This paper explores why.
A Regulatory Reform, or a Business Transformation?
Much of the discussion surrounding the EU Pharma Package has focused on individual legislative provisions:
- revised regulatory protection periods
- new incentive mechanisms
- strengthened shortage prevention requirements
- simplified regulatory procedures
These changes are important. However, taken individually, they risk obscuring the broader transformation taking place.
The real message from European policymakers is that regulatory incentives will increasingly reward medicines that generate measurable value for patients and healthcare systems.
Scientific innovation remains essential. But scientific innovation alone is no longer sufficient.
Future success will depend on an organisation’s ability to integrate regulatory strategy, clinical development, market access and supply resilience into a coherent business model.
The Pharmaceutical Package therefore represents a shift from regulatory compliance to regulatory value creation.
Five Strategic Shifts Every Pharmaceutical Company Should Anticipate
Shift 1: From Regulatory Compliance to Strategic Value Creation
Historically, Regulatory Affairs has focused on obtaining and maintaining marketing authorisations.
Tomorrow, Regulatory Affairs will influence portfolio prioritisation, investment decisions and lifecycle planning.
Questions such as:
- Is this asset likely to benefit from future incentives?
- Does our development strategy support future access expectations?
- How resilient is the regulatory value proposition?
will increasingly be discussed long before submission.
Regulatory strategy becomes part of business strategy.
Shift 2: From Sequential Functions to Integrated Decision-Making
The traditional development model has often followed a linear path: Clinical, then Regulatory, then Market Access, then Commercial.
The new framework makes this approach increasingly unsustainable.
Evidence generation, comparator selection, HTA expectations and regulatory requirements are becoming progressively interconnected.
Companies will need earlier collaboration between:
- Regulatory Affairs
- Clinical Development
- Medical Affairs
- Market Access
- Supply Chain
- Quality
Competitive advantage will depend on organisational integration rather than functional excellence alone.
Shift 3: From Protecting Exclusivity to Earning Incentives
One of the most significant conceptual changes introduced by the reform is that regulatory incentives become increasingly conditional.
Protection is no longer simply granted.
It must increasingly be earned through:
- addressing unmet medical needs
- generating meaningful evidence
- supporting timely patient access
- meeting broader public health objectives
This fundamentally changes lifecycle strategy.
Portfolio decisions should therefore include regulatory scenario planning much earlier than they traditionally have.
Shift 4: From Supply Management to Supply Resilience
Medicine shortages have become a strategic priority for European policymakers.
Consequently, supply continuity is no longer viewed solely as an operational responsibility. It is becoming a regulatory expectation.
Companies should anticipate:
- greater scrutiny of supply risks
- stronger governance requirements
- closer interaction between Regulatory Affairs and Operations
Resilient supply chains are becoming part of the overall product value proposition.
Shift 5: From Responding to Regulation to Anticipating Regulation
Perhaps the biggest change is cultural.
Historically, many organisations have interpreted regulation once legislation had been adopted.
The Pharmaceutical Package requires companies to anticipate change years before implementation.
This demands:
- continuous regulatory intelligence
- strategic scenario planning
- cross-functional governance
- executive-level awareness of regulatory risks
Preparation becomes a competitive advantage.
Five Questions Every Leadership Team Should Be Asking Today
The transition period before the new legislation becomes fully applicable may create the impression that there is still time to prepare.
In reality, many of the decisions that will determine future competitiveness are already being made today.
The companies that will benefit most from the new regulatory environment are not necessarily those that react faster once the legislation applies. They are those that start asking different strategic questions now.
1. Are We Still Prioritising Our Portfolio Using Yesterday’s Criteria?
Traditionally, portfolio decisions have been driven by scientific opportunity, commercial potential and development risk.
The EU Pharmaceutical Package introduces additional variables that may significantly influence long-term value:
- eligibility for regulatory incentives
- evidence expectations
- access considerations
- supply resilience
The question is no longer simply “Can we develop this product?”
It becomes: “Will this product create sustainable regulatory and commercial value under tomorrow’s framework?”
2. Are Regulatory Decisions Being Taken Early Enough?
In many organisations, Regulatory Affairs still enters the conversation once development strategy has largely been defined.
Yet many of the most important regulatory risks originate much earlier:
- study design
- comparator selection
- endpoint strategy
- evidence generation
- global development planning
The issue is not whether Regulatory Affairs participates: it is when.
3. Is Our Organisation Optimised for a World That No Longer Exists?
Many pharmaceutical companies continue to operate through highly specialised functions:
- Clinical
- Regulatory
- Market Access
- Supply
Each highly competent. Each largely independent.
The Pharmaceutical Package encourages a different operating model.
The competitive advantage will increasingly come from the quality of interaction between functions, rather than the excellence of each function individually.
4. Are We Measuring Regulatory Success Correctly?
Historically, regulatory performance has often been measured by operational metrics:
- submission timelines
- approval success rates
- compliance indicators
These remain essential.
But future success may depend equally on different indicators:
- quality of early regulatory influence
- alignment between regulatory and access strategy
- contribution to portfolio decisions
- organisational readiness
The scope of Regulatory Affairs is expanding: its metrics should evolve accordingly.
5. Are We Preparing for Compliance, or for Competitive Advantage?
Perhaps the most important question is also the simplest.
Every company will eventually comply with the new legislation.
The real differentiator is whether organisations use the transition period merely to update procedures, or to rethink how regulatory strategy contributes to business performance.
The Pharmaceutical Package creates an opportunity to redesign decision-making, not just documentation.
Turning Regulatory Change Into Strategic Decisions: Where Arithmos Creates Value
Regulatory transformation rarely fails because organisations misunderstand legislation.
More often, it fails because they underestimate how deeply regulatory change affects business decisions.
At Arithmos, we work alongside pharmaceutical companies to bridge this gap.
Rather than focusing exclusively on regulatory execution, we help organisations integrate regulatory thinking into portfolio strategy, development planning, evidence generation and organisational governance.
Our objective is not simply to help clients respond to regulatory change. It is to help them use regulatory change as a catalyst for better decisions.
Because in today’s environment, competitive advantage is created long before the submission dossier is assembled.
It is created when strategy, science and regulation evolve together.
Conclusion
The EU Pharmaceutical Package should not be viewed as the end of one regulatory framework.
It marks the beginning of a new strategic model for the European pharmaceutical industry.
Companies that approach this transformation solely as a compliance exercise risk reacting to change.
Those that recognise Regulatory Affairs as a strategic capability have the opportunity to anticipate change, improve decision-making and create lasting competitive advantage.
In the years ahead, regulatory excellence will be measured not only by successful submissions, but by the ability to connect science, policy and business strategy into a single, coherent vision.
Is your organisation ready for the EU Pharma Package?
Arithmos works alongside regulatory, clinical and market access teams to turn the Pharmaceutical Package into a business advantage, not just a compliance exercise.
About the Author
Head of Regulatory Affairs
Giulia began her career in R&D within the PK & Metabolism Department before moving into Regulatory Affairs, where she has built more than 25 years of expertise. Throughout her career, she has led numerous development and regulatory projects, guiding companies through complex submissions such as centralised EU registrations, CTAs, INDs, ODDs, PIPs, MAAs, and NDAs.
Her leadership has been instrumental in two major EU centralised procedures—one that contributed to a $900 million product acquisition, and another involving a life-saving antimicrobial developed in collaboration with the WHO and MMV. She also played a key role in most of the recent company/product acquisitions at her previous organisation.
Giulia brings extensive experience in global regulatory negotiations, having worked closely with authorities including the EMA, FDA, PMDA, and several non-ICH agencies.
About Arithmos
With deep expertise in the Life Science Industry, Arithmos supports companies in their digital transformation journey to achieve the best value from technology-enabled solutions and excellence in business operations.
Arithmos team share extensive knowledge of the full GxP regulated environment for both deliveries of services and technologies, and our domains range from Clinical Development, Quality & Compliance, Pharmaco-Vigilance & Safety and, Regulatory Affairs.